Market capitalization | €10.49b |
Enterprise Value | €22.60b |
PER (TTM) P/E ratio | 21.69 |
EV/FCF (TTM) EV/FCF | 11.67 |
EV/Sales (TTM) EV/Sales | 1.16 |
P/S ratio (TTM) P/S ratio | 0.54 |
P/B ratio (TTM) P/B ratio | 0.75 |
Dividend yield | 3.33% |
Last dividend (FY23) | €1.19 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
23 Analysts have issued a Fresenius Medical Care forecast:
23 Analysts have issued a Fresenius Medical Care forecast:
Mar '24 |
+/-
%
|
||
Turnover | 19,474 19,474 |
0%
0%
|
|
Gross income | 4,950 4,950 |
5%
5%
|
|
EBITDA | 3,487 3,487 |
10%
10%
|
EBIT (operating result) EBIT | 1,774 1,774 |
37%
37%
|
Net profit | 484 484 |
20%
20%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 119,845 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.